Sparx Therapeutics, a US-headquartered, research-based development-stage biopharmaceutical company, announced its plan to build a 1.2 million-ft2 manufacturing facility in Yangzhou, China. As part of its plans, the company intends to build a 400,000-ft2 current good manufacturing practice (CGMP) cleanroom on a 10-acre parcel of land. The facility will have a total bioreactor capacity of 80,000 litres housed in separate cleanroom suites, with the capability to support the manufacturing needs of five commercial products in parallel. Source: Biopharm International 9/7/2021